Loading...
Market
Which injectable PrEP will dominate the market in South Africa by end of 2025?
2
Resolution / Starting Odds
Lenacapavir • 25%
Cabotegravir • 25%
Both equally • 25%
Neither dominates • 25%
Market research reports and sales data from pharmaceutical companies
Story
Lenacapavir Reduces HIV Infection Risk to Nearly 0% in Phase 3 Trial, Injectable Every Six Months
Dec 8, 2024, 03:45 PM
Lenacapavir, a novel pre-exposure prophylaxis (PrEP), has shown promising results in reducing the risk of HIV infection to nearly 0% in a phase 3 trial involving adolescent girls and young women in South Africa and Uganda. Unlike traditional vaccines, lenacapavir is an antiretroviral drug that inhibits HIV replication rather than training the immune system to recognize the virus. It is administered just under the skin every six months. Additionally, another injectable PrEP, cabotegravir, is available, requiring an injection every two months. Both options provide new avenues for HIV prevention, highlighting the evolving landscape of antiretroviral therapies.
View original story
Similar markets
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Novartis • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Higher adoption than oral PrEP • 25%
Equal adoption to oral PrEP • 25%
Lower adoption than oral PrEP • 25%
Data not sufficient to determine • 25%
GSK • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Adolescent girls • 25%
Gender-diverse individuals • 25%
General adult population • 25%
Other • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 10% • 25%
10%-30% • 25%
31%-50% • 25%
More than 50% • 25%
Sunlenca surpasses Truvada • 33%
Sunlenca equals Truvada • 34%
Truvada retains lead • 33%
Less than 50 countries • 25%
50 to 80 countries • 25%
81 to 120 countries • 25%
More than 120 countries • 25%
USA • 25%
UK • 25%
South Africa • 25%
Other • 25%